 Navin Pinto
Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 16 | 2025 | 174 | 3.940 |
Why?
| | Neoplasm Recurrence, Local | 8 | 2025 | 1150 | 1.180 |
Why?
| | Immunotherapy, Adoptive | 6 | 2025 | 343 | 1.180 |
Why?
| | B7 Antigens | 3 | 2025 | 18 | 1.110 |
Why?
| | B7-H1 Antigen | 2 | 2019 | 244 | 0.940 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2021 | 883 | 0.890 |
Why?
| | Neoplasms | 6 | 2024 | 2913 | 0.840 |
Why?
| | Cyclophosphamide | 2 | 2024 | 272 | 0.840 |
Why?
| | Salvage Therapy | 3 | 2021 | 165 | 0.790 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 8 | 2025 | 1969 | 0.740 |
Why?
| | Medical Oncology | 3 | 2025 | 340 | 0.710 |
Why?
| | Rhabdomyosarcoma | 1 | 2021 | 65 | 0.640 |
Why?
| | N-Myc Proto-Oncogene Protein | 3 | 2025 | 11 | 0.570 |
Why?
| | Prognosis | 11 | 2025 | 4330 | 0.550 |
Why?
| | Lymphoma | 1 | 2019 | 241 | 0.530 |
Why?
| | Programmed Cell Death 1 Ligand 2 Protein | 1 | 2017 | 14 | 0.520 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 198 | 0.510 |
Why?
| | Child | 26 | 2025 | 22740 | 0.480 |
Why?
| | Infant | 18 | 2025 | 10091 | 0.480 |
Why?
| | T-Lymphocytes | 6 | 2025 | 1998 | 0.440 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 266 | 0.430 |
Why?
| | Gene Amplification | 4 | 2025 | 118 | 0.430 |
Why?
| | Biomarkers, Tumor | 3 | 2022 | 1329 | 0.430 |
Why?
| | Neoplasm Staging | 5 | 2025 | 1475 | 0.430 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2019 | 992 | 0.390 |
Why?
| | Child, Preschool | 17 | 2025 | 11868 | 0.380 |
Why?
| | Brain Stem Neoplasms | 2 | 2025 | 87 | 0.380 |
Why?
| | Melanoma | 1 | 2019 | 762 | 0.380 |
Why?
| | 3-Iodobenzylguanidine | 4 | 2025 | 13 | 0.350 |
Why?
| | Central Nervous System Neoplasms | 2 | 2025 | 177 | 0.350 |
Why?
| | Pharmacogenetics | 2 | 2024 | 175 | 0.340 |
Why?
| | Fibrosarcoma | 2 | 2022 | 23 | 0.340 |
Why?
| | Disease-Free Survival | 3 | 2022 | 770 | 0.310 |
Why?
| | Soft Tissue Neoplasms | 2 | 2022 | 131 | 0.310 |
Why?
| | Adolescent | 17 | 2025 | 22577 | 0.300 |
Why?
| | Survival Rate | 5 | 2025 | 2094 | 0.300 |
Why?
| | Stem Cell Transplantation | 2 | 2018 | 189 | 0.250 |
Why?
| | Pediatrics | 1 | 2015 | 1125 | 0.250 |
Why?
| | Follow-Up Studies | 6 | 2025 | 5428 | 0.240 |
Why?
| | Humans | 33 | 2025 | 145783 | 0.240 |
Why?
| | Young Adult | 10 | 2025 | 14254 | 0.220 |
Why?
| | Wilms Tumor | 1 | 2025 | 90 | 0.210 |
Why?
| | Vincristine | 2 | 2021 | 144 | 0.200 |
Why?
| | Brain Neoplasms | 2 | 2023 | 1331 | 0.190 |
Why?
| | Genes, myc | 1 | 2023 | 51 | 0.190 |
Why?
| | Chromosome Deletion | 1 | 2023 | 126 | 0.190 |
Why?
| | Survivors | 2 | 2016 | 523 | 0.180 |
Why?
| | Osteosarcoma | 1 | 2023 | 89 | 0.180 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2023 | 534 | 0.180 |
Why?
| | Male | 17 | 2025 | 73011 | 0.180 |
Why?
| | Dactinomycin | 1 | 2021 | 23 | 0.170 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 161 | 0.170 |
Why?
| | Female | 17 | 2025 | 79045 | 0.170 |
Why?
| | Kidney Neoplasms | 1 | 2025 | 415 | 0.160 |
Why?
| | Genomics | 2 | 2023 | 830 | 0.160 |
Why?
| | Whole Genome Sequencing | 1 | 2021 | 178 | 0.160 |
Why?
| | Adult | 13 | 2025 | 40881 | 0.160 |
Why?
| | Bone Neoplasms | 1 | 2023 | 265 | 0.160 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2020 | 41 | 0.150 |
Why?
| | Loss of Heterozygosity | 1 | 2019 | 52 | 0.140 |
Why?
| | Cohort Studies | 2 | 2019 | 6033 | 0.140 |
Why?
| | Radionuclide Imaging | 1 | 2018 | 116 | 0.140 |
Why?
| | Endocrine System Diseases | 1 | 2018 | 35 | 0.140 |
Why?
| | Isotretinoin | 1 | 2018 | 26 | 0.140 |
Why?
| | Leukapheresis | 1 | 2018 | 27 | 0.140 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2021 | 673 | 0.140 |
Why?
| | Growth Disorders | 1 | 2018 | 89 | 0.130 |
Why?
| | Glioma | 1 | 2022 | 429 | 0.130 |
Why?
| | Maximum Tolerated Dose | 1 | 2018 | 211 | 0.130 |
Why?
| | Glioblastoma | 1 | 2021 | 354 | 0.130 |
Why?
| | Combined Modality Therapy | 4 | 2025 | 1271 | 0.130 |
Why?
| | Prospective Studies | 4 | 2022 | 8078 | 0.130 |
Why?
| | Immunoenzyme Techniques | 1 | 2017 | 200 | 0.120 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2024 | 2181 | 0.120 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2018 | 289 | 0.120 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2022 | 699 | 0.120 |
Why?
| | Neoadjuvant Therapy | 1 | 2019 | 467 | 0.110 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 102 | 0.110 |
Why?
| | Leukemia | 1 | 2018 | 246 | 0.110 |
Why?
| | Diffusion of Innovation | 1 | 2015 | 96 | 0.110 |
Why?
| | International Cooperation | 1 | 2015 | 197 | 0.110 |
Why?
| | Risk Factors | 3 | 2019 | 10919 | 0.100 |
Why?
| | Interdisciplinary Communication | 1 | 2015 | 201 | 0.100 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 1192 | 0.100 |
Why?
| | Nuclear Proteins | 1 | 2019 | 740 | 0.100 |
Why?
| | Logistic Models | 1 | 2019 | 2139 | 0.100 |
Why?
| | Age of Onset | 1 | 2015 | 557 | 0.100 |
Why?
| | Cancer Survivors | 1 | 2018 | 338 | 0.100 |
Why?
| | Cooperative Behavior | 1 | 2015 | 463 | 0.090 |
Why?
| | Retrospective Studies | 4 | 2022 | 17330 | 0.080 |
Why?
| | ErbB Receptors | 2 | 2025 | 635 | 0.080 |
Why?
| | Induction Chemotherapy | 2 | 2022 | 88 | 0.080 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 2123 | 0.080 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2016 | 688 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2668 | 0.070 |
Why?
| | Transplantation, Autologous | 2 | 2022 | 301 | 0.070 |
Why?
| | Risk Assessment | 2 | 2016 | 3752 | 0.070 |
Why?
| | RNA, Messenger | 1 | 2017 | 2805 | 0.070 |
Why?
| | Infant, Newborn | 2 | 2022 | 6465 | 0.070 |
Why?
| | Autografts | 2 | 2018 | 55 | 0.070 |
Why?
| | Antibodies, Monoclonal | 2 | 2025 | 1505 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 2 | 2023 | 981 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2022 | 11794 | 0.050 |
Why?
| | Time Factors | 1 | 2015 | 7134 | 0.050 |
Why?
| | Area Under Curve | 1 | 2024 | 332 | 0.050 |
Why?
| | Lactams | 1 | 2023 | 28 | 0.050 |
Why?
| | Lactams, Macrocyclic | 1 | 2023 | 51 | 0.050 |
Why?
| | Catheters | 1 | 2023 | 74 | 0.050 |
Why?
| | Gene Fusion | 1 | 2022 | 30 | 0.050 |
Why?
| | Aminopyridines | 1 | 2023 | 129 | 0.050 |
Why?
| | Oncogenes | 1 | 2022 | 118 | 0.040 |
Why?
| | Neoplasm, Residual | 1 | 2022 | 143 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2023 | 169 | 0.040 |
Why?
| | Microtubule-Associated Proteins | 1 | 2022 | 194 | 0.040 |
Why?
| | Chemokine CXCL10 | 1 | 2021 | 39 | 0.040 |
Why?
| | Chemokine CCL2 | 1 | 2021 | 112 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2022 | 228 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 2 | 2021 | 2399 | 0.040 |
Why?
| | Antigens, CD19 | 1 | 2021 | 128 | 0.040 |
Why?
| | Immunity | 1 | 2021 | 140 | 0.040 |
Why?
| | Oncogene Fusion | 1 | 2020 | 11 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2022 | 441 | 0.040 |
Why?
| | Base Sequence | 1 | 2022 | 2171 | 0.040 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2022 | 431 | 0.040 |
Why?
| | Pyrazoles | 1 | 2023 | 517 | 0.040 |
Why?
| | Egypt | 1 | 2018 | 13 | 0.040 |
Why?
| | Busulfan | 1 | 2018 | 15 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 971 | 0.040 |
Why?
| | Melphalan | 1 | 2018 | 43 | 0.040 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2020 | 212 | 0.030 |
Why?
| | Etoposide | 1 | 2018 | 168 | 0.030 |
Why?
| | Carboplatin | 1 | 2018 | 164 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 936 | 0.030 |
Why?
| | Lymphocyte Count | 1 | 2018 | 165 | 0.030 |
Why?
| | CD3 Complex | 1 | 2018 | 112 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2018 | 205 | 0.030 |
Why?
| | Precision Medicine | 1 | 2021 | 461 | 0.030 |
Why?
| | Transplantation Conditioning | 1 | 2018 | 191 | 0.030 |
Why?
| | Age Factors | 1 | 2024 | 3346 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2016 | 371 | 0.030 |
Why?
| | DNA Repair | 1 | 2016 | 255 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2028 | 0.030 |
Why?
| | Mutation | 1 | 2023 | 4090 | 0.020 |
Why?
| | Disease Progression | 1 | 2018 | 2865 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3418 | 0.020 |
Why?
| | Incidence | 1 | 2016 | 2934 | 0.020 |
Why?
| | Aged | 1 | 2018 | 26217 | 0.010 |
Why?
| | Middle Aged | 1 | 2018 | 36309 | 0.010 |
Why?
|
|
Pinto's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|